Literature DB >> 10147

The urinary excretion profiles of naltrexone in man, monkey, rabbit, and rat.

H E Dayton, C E Inturrisi.   

Abstract

A gas-chromatographic method has been developed for the simultaneous determination of naltrexone, alpha-naltrexol, and beta-naltrexol as trimethylsiyl derivatives. Analysis of urine from rabbit, monkey, and rat demonstrated that, like man, these species reduce naltrexone primarily to beta-naltrexol. In naltrexone maintenance patients receiving 125 mg po three times per week, an average of 37% of the dose was recovered in 48-hr urine as free naltrexone (0.8%), conjugated naltrexone (7.6%), free beta-naltrexol (16.8%), and conjugated beta-naltrexol (11.8%). Thirty-four percent of the dose appeared in 0-24 hr and 3% during 24-48 hr. The ratio of beta-naltrexol to naltrexone rose from 2 at 0-4 hr to 34-48 hr. Monkeys receiving a daily dose of 12 mg/kg po, chronically, excreted very little free beta-naltrexol and exhibited an apparent sex-related difference in excretion patterns, with females excreting more than twice as much total base as males. Rabbits given a dose of 30 mg/kg ip for 4 days excreted conjugated naltrexone as the predominant urinary metabolite, accounting for 80% of total base recovered in 24 hr. In rats receiving 100 mg/kg po, less than 1% of the administered dose could be accounted for in the 24-hr urine, indicating that although the beta-naltrexol is produced as a urinary metabolite, other means of disposition of the drug must exist. Thus, in man and the monkey, beta-naltrexol is the predominant and persistent urinary metabolite. Urinary excretion profiles of naltrexone differ greatly between species commonly examined for chronic toxicity studies.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 10147

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  5 in total

Review 1.  A risk-benefit assessment of naltrexone in the treatment of alcohol dependence.

Authors:  B J Berg; H M Pettinati; J R Volpicelli
Journal:  Drug Saf       Date:  1996-10       Impact factor: 5.606

2.  Naltrexone Maintenance: Effect on Morphine Sensitivity in Normal Volunteers.

Authors:  James W Cornish; David Henson; Sanford Levine; Joseph Volpicelli; Charles E Inturrisi; Byron C Yoburn; Charles P O'Brien
Journal:  Am J Addict       Date:  1993

3.  Kinetics and inhibition of the formation of 6beta-naltrexol from naltrexone in human liver cytosol.

Authors:  S J Porter; A A Somogyi; J M White
Journal:  Br J Clin Pharmacol       Date:  2000-11       Impact factor: 4.335

4.  Disposition of naltrexone after intravenous bolus administration in Wistar rats, low-alcohol-drinking rats and high-alcohol-drinking rats.

Authors:  Emmanuel O Akala; Hu Wang; Adedayo Adedoyin
Journal:  Neuropsychobiology       Date:  2008-10-03       Impact factor: 2.328

Review 5.  Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence.

Authors:  J P Gonzalez; R N Brogden
Journal:  Drugs       Date:  1988-03       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.